FDA Accepts First Biosimilar Application From Sandoz

Law360, New York (July 24, 2014, 12:06 PM EDT) -- Novartis AG unit Sandoz Inc. announced Thursday that the U.S. Food and Drug Administration is reviewing its request to market a biosimilar version of Amgen Inc.'s Neupogen, a milestone that marks the first publicly disclosed application along an Affordable Care Act approval pathway.

The drugmaker already has clearance in more than 40 countries for its biosimilar of Neupogen, or filgrastim. The application for FDA approval comes more than four years after passage of the Biologics Price Competition and Innovation Act, an ACA section that aims to cut the costs of pricey biologic medications just as Hatch-Waxman did three decades ago for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!